Literature DB >> 19386851

Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

Shawn A Messer1, Gary J Moet, Jeffrey T Kirby, Ronald N Jones.   

Abstract

Results from the SENTRY international fungal surveillance program for 2006 to 2007 are presented. A total of 1,448 Candida sp., 49 Aspergillus fumigatus, and 33 Cryptococcus neoformans isolates were obtained from infected sterile-site sources in patients on five continents. Reference susceptibility was determined for anidulafungin, caspofungin, 5-flucytosine, fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B by CLSI methods.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19386851      PMCID： PMC2691076          DOI： 10.1128/JCM.02434-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  12 in total

1.  Quality control parameters for broth microdilution tests of anidulafungin.

Authors:  Karen Krisher; Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003).

Authors:  Michael A Pfaller; Ronald N Jones
Journal:  Arch Pathol Lab Med       Date:  2006-06       Impact factor: 5.534

4.  Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.

Authors:  Ronald N Jones; Jeffrey T Kirby; Shawn A Messer; Daniel J Sheehan
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03-26       Impact factor: 2.803

5.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Initial results from a longitudinal international surveillance programme for anidulafungin (2003).

Authors:  Shawn A Messer; Jeffrey T Kirby; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2004-11-25       Impact factor: 5.790

7.  International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

Authors:  Shawn A Messer; Ronald N Jones; Thomas R Fritsche
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

8.  Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.

Authors:  A Espinel-Ingroff; A Fothergill; M Ghannoum; E Manavathu; L Ostrosky-Zeichner; M A Pfaller; M G Rinaldi; W Schell; T J Walsh
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

9.  In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

10.  In vitro activity of anidulafungin against selected clinically important mold isolates.

Authors:  Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
View more
  32 in total

1.  Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).

Authors:  Shawn A Messer; Ronald N Jones; Gary J Moet; Jeffrey T Kirby; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

2.  In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.

Authors:  Sharon C-A Chen; Chayanika Biswas; Robyn Bartley; Fred Widmer; Namfon Pantarat; Daniel Obando; Julianne T Djordjevic; David H Ellis; Katrina A Jolliffe; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

3.  Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.

Authors:  Ronald N Jones; Mariana Castanheira; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

Authors:  M A Pfaller; R Hollis; B P Goldstein; S Messer; D Diekema; T Henkel
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

5.  In vitro susceptibility of Candida isolates from organ transplant recipients to newer antifungals.

Authors:  Alexandra Geusau; Lukasz Antoniewicz; Christine Poitschek; Elisabeth Presterl; Birgit Willinger
Journal:  Mycopathologia       Date:  2014-03-29       Impact factor: 2.574

6.  Ten-year study of species distribution and antifungal susceptibilities of Candida bloodstream isolates at a Brazilian tertiary hospital.

Authors:  L X Bonfietti; M W Szeszs; M R Chang; M A Martins; S R B S Pukinskas; M O Nunes; G H Pereira; A M M Paniago; S U Purisco; M S C Melhem
Journal:  Mycopathologia       Date:  2012-07-21       Impact factor: 2.574

7.  Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study.

Authors:  Roberto Luzzati; Maria Merelli; Filippo Ansaldi; Chiara Rosin; Annamaria Azzini; Silvia Cavinato; Pierluigi Brugnaro; Claudio Vedovelli; Annamaria Cattelan; Busetti Marina; Giuseppe Gatti; Ercole Concia; Matteo Bassetti
Journal:  Infection       Date:  2016-07-11       Impact factor: 3.553

8.  Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Authors:  Mariana Castanheira; Leah N Woosley; Daniel J Diekema; Shawn A Messer; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

9.  Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.

Authors:  S J Taj-Aldeen; A Kolecka; R Boesten; A Alolaqi; M Almaslamani; P Chandra; J F Meis; T Boekhout
Journal:  Infection       Date:  2013-12-19       Impact factor: 3.553

10.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.